Myomo Inc. (MYO)
| Market Cap | 56.67M |
| Revenue (ttm) | 7.58M |
| Net Income (ttm) | -12.23M |
| Shares Out | 3.33M |
| EPS (ttm) | -3.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $9.91 |
| Previous Close | $10.15 |
| Change ($) | -0.24 |
| Change (%) | -2.36% |
| Day's Open | 9.92 |
| Day's Range | 9.74 - 10.13 |
| Day's Volume | 38,664 |
| 52-Week Range | 3.42 - 18.88 |
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 21.28% and 14.50%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi...
Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company offering increased functionality for individuals suffering from neurol...
Myomo, Inc.'s (MYO) CEO Paul Gudonis on Q3 2020 Results - Earnings Call Transcript
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologi...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurologic...
Myomo (MYO) is in the news Wednesday following an announcement about Medicare authorization that sent MYO stock soaring higher. The post Myomo News: MYO Stock Surges 32% on Medicare Authorization appear...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.
Myomo, Inc.'s (MYO) CEO Paul Gudonis on Q2 2020 Results - Earnings Call Transcript
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 14.50% and 43.17%, respectively, for the quarter ended June 2020.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.
Myomo, Inc. (MYO) CEO Paul Gudonis on Q1 2020 Results - Earnings Call Transcript
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -29.38% and 29.23%, respectively, for the quarter ended March 2020.
Myomo's (MYO) CEO Paul Gudonis on Q4 2019 Results - Earnings Call Transcript
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -7.37% and 8.64%, respectively, for the quarter ended December 2019.
Myomo, Inc. (MYO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Myomo Inc (NYSE: MYO) shares ran wild Tuesday and the momentum continued in Wednesday's session.
Myomo, Inc. (MYO) CEO Paul Gudonis on Q3 2019 Results - Earnings Call Transcript
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 0.00% and -53.31%, respectively, for the quarter ended September 2019.
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Myomo's (MYO) CEO Paul Gudonis on Q2 2019 Results - Earnings Call Transcript
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Myomo, Inc. (MYO) CEO Paul Gudonis on Q1 2019 Results - Earnings Call Transcript
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 15.00% and -3.49%, respectively, for the quarter ended March 2019.
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
About MYO
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord inj... [Read more...]
| Industry Medical Devices | IPO Date Jun 12, 2017 |
| CEO Paul Gudonis | Employees 62 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol MYO |
Financial Performance
In 2020, Myomo's revenue was $7.58 million, an increase of 97.60% compared to the previous year's $3.84 million. Losses were -$11.56 million, 7.94% more than in 2019.
Analyst Forecasts
According to 2 analysts, the average rating for Myomo stock is "Buy." The 12-month stock price forecast is 18.00, which is an increase of 81.63% from the latest price.